Goldman Sachs
BIOTW

Goldman Sachs’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Goldman Sachs’s Portfolio BIOTW Stock Details BIOTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11,240
Closed -$7K – 6671
2021
Q1 		$7K Buy
+11,240
New +$7.92K ﹤0.01% 6030

Other funds holding BIOTW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RA
Ramius Advisors New York $95.2M AUM 7.33% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
KCM
Kingstown Capital Management New York $30.4M AUM 3.71% 1-Year Est. Return
ACM
Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Goldman Sachs's BIOTW Position: Q2 2021 in Review

Goldman Sachs sold out of Biotech Acquisition Company Warrant (BIOTW) in Q2 2021, closing a stake of 11,240 shares — an estimated $7K sold.

Goldman Sachs first reported a position in BIOTW in Q1 2021 and held it in 1 quarter. The position peaked at $7K in Q1 2021. 34 funds tracked by Wall St. Rank hold BIOTW as of Q2 2021.

  • Goldman Sachs reported no remaining Biotech Acquisition Company Warrant position as of Q2 2021 after selling out during the quarter.
  • Goldman Sachs sold 11,240 Biotech Acquisition Company Warrant shares in Q2 2021, an estimated $7K.
  • Goldman Sachs first reported a position in Biotech Acquisition Company Warrant in Q1 2021 and held it in 1 quarter.
  • Goldman Sachs's Biotech Acquisition Company Warrant position peaked at $7K in Q1 2021.
  • 34 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q2 2021.

Based on Goldman Sachs's 13F filing for Q2 2021, filed 13 Aug 2021.